107 related articles for article (PubMed ID: 30545466)
1. Pharmacology of Symtuza
Curran A; Navarro J
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():10-16. PubMed ID: 30545466
[TBL] [Abstract][Full Text] [Related]
2. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
4. Symtuza
Gómez Ayerbe C; Santos González J; Palacios Muñoz R
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():17-21. PubMed ID: 30545467
[TBL] [Abstract][Full Text] [Related]
5. Symtuza
Galindo Puerto MJ
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():22-30. PubMed ID: 30545468
[TBL] [Abstract][Full Text] [Related]
6. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2018 Jul; 78(10):1013-1024. PubMed ID: 29915897
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Negredo E; Clotet B
Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
[TBL] [Abstract][Full Text] [Related]
9. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
10. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Cevik M; Orkin C
Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
[TBL] [Abstract][Full Text] [Related]
11. Symtuza
Luis Casado J; Fontecha M; Monsalvo M; Vizcarra P
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():31-36. PubMed ID: 30545470
[TBL] [Abstract][Full Text] [Related]
12. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults.
Muccini C; Castagna A
Expert Rev Anti Infect Ther; 2023; 21(11):1167-1176. PubMed ID: 37800640
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of Current Antiretroviral Single-Tablet Regimens.
Domingo P; Mateo MG; Gutierrez MDM; Vidal F
AIDS Rev; 2018; 20(3):141-149. PubMed ID: 30264826
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Llaves S; Fernandez-Magdaleno T; Espinosa N; Viciana P; Lopez-Cortes LF
J Antimicrob Chemother; 2017 Mar; 72(3):816-819. PubMed ID: 27999051
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
17. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
[TBL] [Abstract][Full Text] [Related]
19. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
[TBL] [Abstract][Full Text] [Related]
20. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
